Skip to main content

Table 4 Response in measurable lesions

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Groups

N

CR

PR

SD

PD

ORR (%)

DCR (%)

P value*

All patients

45

0

14

22

9

31.8

77.3

0.54

No ascites

28

0

11

14

3

39.2

89.2

 

Small to moderate ascites

12

0

2

6

4

16.7

66.7

 

Massive ascites

5

0

1

2

2

20.0

60.0

 
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate (CR + PR + SD)
  2. *Comparison of ORR between 3 groups
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us